Search
Displaying 81–90 of 663 for “retinitis clinical trial”
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
Luxa Reports Vision Improvements in Clinical Trial of its RPE Stem Cell Therapy for Dry AMD
Research NewsPatients with worse vision at trial enrollment had greatest vision improvements.
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Research NewsKnown as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
Retinal Patch Performs Promisingly in Clinical Trial for Dry AMD Patients
Research NewsRegenerative Patch Technologies, a company developing stem-cell-derived treatments for people with retinal diseases, has reported encouraging results for the first five patients with advanced, dry age-related macular degeneration (AMD) participating in a Phase I/IIa clinical trial for its therapy – a patch comprised of a layer of retinal pigment epithelial (RPE) cells on a synthetic scaffold.
-
Vision Improvements Reported in ProQR's Clinical Trial for LCA10 Treatment
Research NewsThe company reported that 60 percent of subjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course. The treatment was also safe for patients.
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Positive Interim Clinical Trial Results for Adverum’s Wet AMD Gene Therapy
Research NewsThe gene therapy is designed to reduce the treatment burden for patients
-
Apellis Launches Phase 3 Clinical Trial Program for Advanced Dry AMD Treatment
Research NewsTrial participants will receive intravitreal injections of APL-2, or a sham procedure (placebo), monthly or every other month. The injections are made into the vitreous, the soft gel in the middle of the eye.
